Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BMEA
stocks logo

BMEA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.230
-71.55%
--
--
-0.270
-66.25%
--
--
-0.230
-54.9%
Estimates Revision
Stock Price
Go Down
down Image
-38.02%
In Past 3 Month
Wall Street analysts forecast BMEA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMEA is 7.17 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast BMEA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMEA is 7.17 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
1 Sell
Moderate Buy
Current: 1.190
sliders
Low
4.00
Averages
7.17
High
12.00
Current: 1.190
sliders
Low
4.00
Averages
7.17
High
12.00
JPMorgan
Neutral -> Underweight
downgrade
2025-11-15
Reason
JPMorgan
Price Target
2025-11-15
downgrade
Neutral -> Underweight
Reason
JPMorgan downgraded Biomea Fusion to Underweight from Neutral without a price target. The firm views the recent phase 2 COVALENT II icovamenib data in type 2 diabetes as "interesting" but has concerns around the company's ability to fund the ongoing and planned studies. The funding may come with significant dilution over the long-term without a partnership, which is difficult to predict, the analyst tells investors in a research note.
Citi
Buy
downgrade
$7 -> $6
2025-11-10
Reason
Citi
Price Target
$7 -> $6
2025-11-10
downgrade
Buy
Reason
Citi lowered the firm's price target on Biomea Fusion to $6 from $7 and keeps a Buy rating on the shares following the Q3 report. The firm cites the company's higher spending and dilution from the recent public offering for the target drop.
D. Boral Capital
Buy
downgrade
$16 -> $12
2025-11-05
Reason
D. Boral Capital
Price Target
$16 -> $12
2025-11-05
downgrade
Buy
Reason
D. Boral Capital lowered the firm's price target on Biomea Fusion to $12 from $16 and keeps a Buy rating on the shares following the Q3 report. The firm cites the new share count for the target drop.
Jefferies
Buy
initiated
$5
2025-08-28
Reason
Jefferies
Price Target
$5
2025-08-28
initiated
Buy
Reason
Jefferies initiated coverage of Biomea Fusion with a Buy rating and $5 price target. Biomea is a clinical-stage biotech focused on developing oral small molecule for diabetes and obesity medicines, the analyst tells investors in a research note. The firm says the company's lead asset icovamenib is being studied in both type 2 and type 1 diabetes with Phase 2 data updates coming in the second half of 2025. The drug has a mechanism of action that could "fundamentally address a root driver of diabetes," contends Jefferies.
Citi
Yigal Nochomovitz
Buy
downgrade
$9 -> $7
2025-08-11
Reason
Citi
Yigal Nochomovitz
Price Target
$9 -> $7
2025-08-11
downgrade
Buy
Reason
Citi analyst Yigal Nochomovitz lowered the firm's price target on Biomea Fusion to $7 from $9 and keeps a Buy rating on the shares. The firm cites the recent share dilution for the target cut but sees a good setup for the stock into the company's second half of 2025 updates.
Scotiabank
Outperform
to
NULL
downgrade
$30 -> $10
2025-08-06
Reason
Scotiabank
Price Target
$30 -> $10
2025-08-06
downgrade
Outperform
to
NULL
Reason
Scotiabank lowered the firm's price target on Biomea Fusion to $10 from $30 and keeps an Outperform rating on the shares. The firm cut its price target on the stock due to the extended icovamenib type-2 diabetes timelines, reflecting the need for an additional Phase 2b study prior to any Phase 3 study, as well as increased equity dilution, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Biomea Fusion Inc (BMEA.O) is -1.23, compared to its 5-year average forward P/E of -3.76. For a more detailed relative valuation and DCF analysis to assess Biomea Fusion Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.76
Current PE
-1.23
Overvalued PE
-0.90
Undervalued PE
-6.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.35
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.07
Undervalued EV/EBITDA
-6.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BMEA News & Events

Events Timeline

(ET)
2025-12-05
07:10:00
New
Biomea Fusion Presents COVALENT-111 Study Results at WCIRDC
select
2025-11-05 (ET)
2025-11-05
07:37:05
Biomea Fusion to Present Two Posters on BMF-650 and Icovamenib
select
2025-11-04 (ET)
2025-11-04
16:56:43
Biomea Fusion announces Q3 earnings per share of 27 cents, below consensus estimate of 29 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
20:21 PMGlobenewswire
Biomea Fusion Presents COVALENT-111 Study Results, New Breakthrough in Diabetes Treatment
  • Study Results Presentation: Biomea Fusion presented COVALENT-111 study results at the WCIRDC in Los Angeles, demonstrating that icovamenib achieved durable improvements in HbA1c and C-peptide in patients with severe insulin-deficient type 2 diabetes, indicating its potential in diabetes treatment.
  • Significant Clinical Effects: The study results showed a notable correlation between icovamenib use and HbA1c reduction, with treatment effects persisting nine months post last dose, suggesting its long-term efficacy.
  • Good Safety Profile: In clinical trials, icovamenib was well-tolerated with no discontinuations due to adverse events, indicating a high safety profile that could enhance market acceptance among patients.
  • Future Development Potential: As the first non-chronic therapy for type 2 diabetes, icovamenib could represent a significant innovation in diabetes treatment if it successfully completes ongoing clinical studies, addressing the growing global demand for diabetes management solutions.
[object Object]
Preview
2.0
12-03NASDAQ.COM
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain

  • Clene Inc. Gains: Clene Inc. shares rose 8.53% in after-hours trading after announcing an upcoming investor call regarding its CNM-Au8 program for ALS, despite a regular session decline.

  • Werewolf Therapeutics Update: Werewolf Therapeutics saw a 6.12% increase after hours, likely influenced by investor reactions to its recent presentation at a cancer immunotherapy conference, despite no new news.

  • Biomea Fusion Presentation: Biomea Fusion's stock climbed 7.31% after hours following its announcement of an upcoming presentation on icovamenib data at a major diabetes and cardiovascular disease congress.

  • General Market Trends: Other biotech companies like Denali Therapeutics, TScan Therapeutics, and Nyxoah also experienced after-hours gains, reflecting ongoing investor interest and positioning ahead of regulatory milestones and presentations.

[object Object]
Preview
5.0
12-02Newsfilter
Biomea Fusion Grants 7,500 Stock Options to New Employee
  • Employee Incentive Program: On November 26, 2025, Biomea Fusion granted 7,500 non-qualified stock options to a new employee, aiming to attract talent and enhance employee loyalty, which will strengthen the company's competitive position in diabetes and obesity drug development.
  • Vesting Structure: The stock options will vest quarterly at a rate of 1/16 over four years, contingent on the employee's continued employment, a structure that not only helps retain key talent but also aligns employee interests with the company's long-term goals.
  • Incentive Plan Context: This stock option grant is made under Biomea's 2023 Inducement Equity Plan, adopted on November 17, 2023, in compliance with Nasdaq Listing Rule 5635(c)(4), highlighting the company's strategic focus on talent acquisition and retention.
  • Market Positioning: Biomea Fusion is dedicated to developing oral small molecules for diabetes and obesity, addressing a global health challenge, and aims to improve patient quality of life through innovative treatment solutions, thereby securing a foothold in the rapidly growing healthcare market.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Biomea Fusion Inc (BMEA) stock price today?

The current price of BMEA is 1.19 USD — it has increased 13.33 % in the last trading day.

arrow icon

What is Biomea Fusion Inc (BMEA)'s business?

Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.

arrow icon

What is the price predicton of BMEA Stock?

Wall Street analysts forecast BMEA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMEA is 7.17 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Biomea Fusion Inc (BMEA)'s revenue for the last quarter?

Biomea Fusion Inc revenue for the last quarter amounts to -18.60M USD, decreased -45.36 % YoY.

arrow icon

What is Biomea Fusion Inc (BMEA)'s earnings per share (EPS) for the last quarter?

Biomea Fusion Inc. EPS for the last quarter amounts to -11550000.00 USD, decreased -54.53 % YoY.

arrow icon

What changes have occurred in the market's expectations for Biomea Fusion Inc (BMEA)'s fundamentals?

The market is revising No Change the revenue expectations for BMEA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -38.02%.
arrow icon

How many employees does Biomea Fusion Inc (BMEA). have?

Biomea Fusion Inc (BMEA) has 106 emplpoyees as of December 05 2025.

arrow icon

What is Biomea Fusion Inc (BMEA) market cap?

Today BMEA has the market capitalization of 84.14M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free